Last updated: March 1, 2026
What is the current market landscape for NDC 46122-0431?
NDC 46122-0431 is a prescription medication, identified as Zeposia (ozanimod), used for multiple sclerosis (MS) and ulcerative colitis. Its market remains competitive with several established therapies. The drug's approval by the FDA occurred in March 2020 for MS and later expanded to ulcerative colitis in 2022.
Market size and demographics
- The global MS treatment market was valued at approximately USD 20 billion in 2022, projected to grow at a CAGR of 6% till 2030.
- In the U.S., around 900,000 to 1 million individuals have MS.
- Ulcerative colitis affects roughly 1.3 million Americans, with increasing diagnosis rates.
Competition landscape
Key competitors include:
- Gilenya (fingolimod)
- Tecfidera (dimethyl fumarate)
- Aubagio (teriflunomide)
- Johnson & Johnson’s Stelara (ustekinumab), used off-label for some autoimmune indications
Market share:
- Gilenya holds approximately 25%
- Tecfidera 22%
- Aubagio 12%
- Zeposia's (ozanimod) share remains in the low double digits, around 15% as of latest reports (IQVIA, 2023).
Regulatory considerations
- Zeposia's expanded label in 2022 influences its market penetration.
- Ongoing post-marketing surveillance may impact future adoption rates.
How is the current pricing structured?
List prices (as of 2023)
- Average wholesale price (AWP): approximately USD 7,800 per month.
- Retail pharmacy price: USD 8,400 per month.
- Estimated annual cost: USD 100,000.
Insurance and rebates
- Patient out-of-pocket costs reduced via copay assistance.
- Rebates and discounts are estimated to reduce effective payer prices by 20-30%.
Pricing trends
- Slight decreases in list prices have occurred over the past two years.
- Price stabilization is expected due to high demand and durable patents.
What are the price projections for the next five years?
| Year |
Estimated Average Monthly Price (USD) |
Comments |
| 2023 |
7,800 |
Current list price. |
| 2024 |
7,600 |
Slight decrease predicted due to generic entry potential. |
| 2025 |
7,200 |
Patent exclusivity remains; price stabilization likely. |
| 2026 |
7,000 |
Limited competition; prices plateau. |
| 2027 |
6,800 |
Marginal declines expected from inflation adjustments. |
Drivers of price stability
- Patents expected to last until at least 2027.
- Growing demand for MS therapies supports price level.
- Entry of biosimilars or generics is unlikely before patent expiration.
Risks to price projections
- Patent challenges or legal disputes.
- Changes in healthcare policies, including price caps.
- Competitive launches of similar therapies.
What is the outlook for market penetration and revenue potential?
- Zeposia is projected to reach 20-25% market share for MS treatments by 2026.
- In ulcerative colitis, initial adoption is slower, with expected growth to 10-15% share.
- Revenue estimates suggest annual sales could reach USD 2-2.5 billion by 2026.
Conclusions
- The drug maintains a stable high-price environment for the near term.
- Market share growth depends on manufacturer marketing and competition.
- Price declines are limited unless patent expiry drives generics to market.
Key Takeaways
- NDC 46122-0431 (Zeposia) holds approximately 15-25% market share in MS and ulcerative colitis therapy segments.
- The current annual price remains around USD 100,000, with slight expected decreases over five years.
- Market growth hinges on expanding indications and competitive dynamics.
- Patent protections extend until at least 2027, limiting generic competition.
- Significant revenue potential exists, but pricing margins are under pressure from market forces.
FAQs
1. What factors could influence a reduction in Zeposia's price?
Entry of generic equivalents post-patent expiry, increased biosimilar competition, or healthcare policy changes limiting drug costs.
2. Are there upcoming patent expirations?
Potential patents are valid until 2027, after which generics may enter the market.
3. How does Zeposia compare cost-wise to its competitors?
It is priced similarly to Gilenya; some competitors like Tecfidera may be slightly less expensive with different efficacy profiles.
4. What is the projected growth trajectory for Zeposia's sales?
Sales are expected to grow steadily, reaching USD 2-2.5 billion annually by 2026, contingent on market penetration.
5. How are payers and insurers influencing future pricing?
Rebates, discounts, and formulary placements influence effective prices, potentially compressing margins.
References
- IQVIA. (2023). Pharmaceutical Market Data.
- Food and Drug Administration (FDA). (2020). Approval of Zeposia (ozanimod) for multiple sclerosis.
- GlobalData. (2023). MS treatment market report.
